A Glimmer of Hope: Immunotherapy Trial Transforms Colorectal Cancer Prognosis
Spencer Laird's cancer journey took a devastating turn when, at age 30, a routine follow-up revealed his colorectal cancer had returned and spread aggressively, with 13 tumors in his lungs. Doctors estimated he had approximately two years to live, even with treatment.
Early Diagnosis and a Grim Outlook
Spencer Laird first experienced blood in his stool at 25. Eighteen months later, a colonoscopy confirmed colorectal cancer, leading to surgery to remove 16 inches of his colon.
Two years post-treatment, in December 2024, at age 30, increased fatigue prompted by his wife, CarleyAnn Laird, led to a full body scan. This scan delivered the grim news: the cancer had returned and spread, with 13 tumors in his lungs, one the size of a golf ball. The prognosis was dire, with doctors estimating only two years to live, even with ongoing treatment.
A Search for Alternatives: The Clinical Trial
Laird was diagnosed with microsatellite stable colorectal cancer, a type typically managed with chemotherapy and radiation. Concerned by chemotherapy's side effects and the terminal prognosis, CarleyAnn Laird proactively researched alternative options, applying to several clinical trials.
Their search led them to a promising trial at Duke University, led by gastrointestinal oncologist Dr. Nicholas DeVito. This trial was investigating immunotherapy as a first-line treatment for microsatellite stable colorectal cancer – a significant departure from standard practice, which typically reserves immunotherapy for cases where multiple chemotherapy failures have occurred.
Laird joined the trial in February, becoming one of 15 enrolled patients. Participants receive an immunotherapy infusion every two weeks, with periodic scans to monitor disease progression.
Subsequent scans showed a significant reduction in Laird's tumors, decreasing from 13 to three. The largest remaining tumor measures 0.6 millimeters.
Remarkable Results and Expert Validation
The treatment quickly yielded positive outcomes. Subsequent scans showed a significant reduction in Laird's tumors, decreasing from 13 to three. The largest remaining tumor now measures a mere 0.6 millimeters.
While Laird experienced initial side effects, including rashes, headaches, nausea, and dizziness, these later subsided. Dr. Nicholas DeVito noted Laird had one of the strongest early responses observed in the trial.
Dr. Michael James Overman, an oncologist not involved in Laird's care, described the trial as novel, highlighting its innovative approach. The full results of the trial are eagerly anticipated and are expected to be published in April.